HBW 3210
Alternative Names: HBW-3-10; HBW-3210Latest Information Update: 03 Aug 2022
At a glance
- Originator Chengdu Hyperway Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Chronic lymphocytic leukaemia
- Preclinical Autoimmune disorders
Most Recent Events
- 25 Jul 2022 Clinical trials in Chronic lymphocytic leukaemia in China (PO) as of July 2022 (Chengdu Hyperway Pharmaceuticals pipeline, July 2022)
- 25 Jul 2022 Preclinical trials in Autoimmune disorders in China (PO) (Chengdu Hyperway Pharmaceuticals pipeline, July 2022)
- 03 Aug 2021 Pharmacodynamics and adverse events data from preclinical studies in Chronic lymphocytic leukemia (CLL) presented at 26th Congress of the European Haematology Association